Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation research hub

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

The ZEUS study is looking at whether a new medicine called ziltivekimab can protect people with heart and kidney problems. Researchers want to see if lowering body swelling and inflammation can reduce the chances of serious health events like heart attacks, strokes, or worsening kidney disease.